Campbell & CO Investment Adviser LLC raised its holdings in Hill-Rom Holdings, Inc. (NYSE:HRC) by 47.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,437 shares of the medical technology company’s stock after purchasing an additional 1,100 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Hill-Rom were worth $300,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of HRC. Ceredex Value Advisors LLC acquired a new stake in Hill-Rom in the first quarter valued at approximately $92,503,000. BlackRock Inc. grew its holdings in Hill-Rom by 8.7% in the first quarter. BlackRock Inc. now owns 6,176,659 shares of the medical technology company’s stock valued at $537,367,000 after purchasing an additional 496,435 shares during the period. Amundi Pioneer Asset Management Inc. grew its holdings in Hill-Rom by 10,137.2% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 392,289 shares of the medical technology company’s stock valued at $34,128,000 after purchasing an additional 388,457 shares during the period. Lord Abbett & CO. LLC grew its holdings in Hill-Rom by 29.2% in the first quarter. Lord Abbett & CO. LLC now owns 1,166,497 shares of the medical technology company’s stock valued at $101,485,000 after purchasing an additional 263,612 shares during the period. Finally, Prudential Financial Inc. grew its holdings in Hill-Rom by 53.3% in the first quarter. Prudential Financial Inc. now owns 663,967 shares of the medical technology company’s stock valued at $57,764,000 after purchasing an additional 230,822 shares during the period. 81.15% of the stock is currently owned by institutional investors.

HRC has been the topic of several research analyst reports. Zacks Investment Research lowered Hill-Rom from a “buy” rating to a “hold” rating in a report on Friday, April 6th. KeyCorp reissued an “overweight” rating and issued a $115.00 price objective (up from $97.00) on shares of Hill-Rom in a report on Tuesday. Goldman Sachs Group initiated coverage on Hill-Rom in a report on Wednesday, April 4th. They issued a “neutral” rating and a $85.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and issued a $106.00 price objective (up from $105.00) on shares of Hill-Rom in a report on Monday, April 30th. Finally, ValuEngine lowered Hill-Rom from a “buy” rating to a “hold” rating in a report on Saturday, June 16th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $97.00.

Shares of NYSE:HRC opened at $94.23 on Wednesday. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 1.34. The company has a market capitalization of $6.05 billion, a PE ratio of 24.41, a PEG ratio of 1.42 and a beta of 0.96. Hill-Rom Holdings, Inc. has a 1 year low of $71.91 and a 1 year high of $94.72.

Hill-Rom (NYSE:HRC) last issued its quarterly earnings results on Friday, April 27th. The medical technology company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.02 by $0.03. The firm had revenue of $710.50 million for the quarter, compared to analyst estimates of $707.54 million. Hill-Rom had a return on equity of 20.18% and a net margin of 6.85%. The business’s revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.88 earnings per share. research analysts anticipate that Hill-Rom Holdings, Inc. will post 4.63 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, June 29th. Stockholders of record on Friday, June 22nd were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date was Thursday, June 21st. Hill-Rom’s dividend payout ratio is presently 20.73%.

In other news, SVP Alton Shader sold 16,812 shares of Hill-Rom stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $93.70, for a total value of $1,575,284.40. Following the sale, the senior vice president now directly owns 54,898 shares of the company’s stock, valued at $5,143,942.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Paul Sherwood Johnson sold 5,168 shares of Hill-Rom stock in a transaction that occurred on Friday, May 25th. The stock was sold at an average price of $90.88, for a total value of $469,667.84. Following the completion of the sale, the senior vice president now directly owns 4,063 shares in the company, valued at $369,245.44. The disclosure for this sale can be found here. Insiders own 1.90% of the company’s stock.

About Hill-Rom

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Recommended Story: Should you buy a closed-end mutual fund?

Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.